Bioethics, Ltd.
BOTH
$1.25
$0.70127.27%
OTC PK
09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 293.00% | 55.41% | 126.67% | 52.81% | -4.76% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 293.00% | 55.41% | 126.67% | 52.81% | -4.76% |
Operating Income | -293.00% | -55.41% | -126.67% | -52.81% | 4.76% |
Income Before Tax | -138.12% | -33.96% | -68.22% | -17.87% | -0.45% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -138.12% | -33.96% | -68.22% | -17.87% | -0.45% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -138.12% | -33.96% | -68.22% | -17.87% | -0.45% |
EBIT | -293.00% | -55.41% | -126.67% | -52.81% | 4.76% |
EBITDA | -- | -- | -- | -- | -- |
EPS Basic | -138.78% | -34.32% | -67.79% | -18.13% | 0.00% |
Normalized Basic EPS | -137.40% | -33.78% | -67.69% | -17.54% | -0.82% |
EPS Diluted | -138.78% | -34.32% | -67.79% | -18.13% | 0.00% |
Normalized Diluted EPS | -137.40% | -33.78% | -67.69% | -17.54% | -0.82% |
Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |